Evidence map›Paper›PMID 34781301›Full record

SynthesisCardiology

Identification and Mapping Real-World Data Sources for Heart Failure, Acute Coronary Syndrome, and Atrial Fibrillation.

Rachel Studer, Claudio Sartini, Kiliana Suzart-Woischnik, Rumjhum Agrawal, Harshul Natani, Simrat K Gill, Sara Bruce Wirta, Folkert W Asselbergs, Richard Dobson, Spiros Denaxas and 1 more

Abstract readSystematic Review
In one paragraph

Synthesis in Cardiology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Rachel StuderNovartis Pharma AG, Novartis Campus, Basel, Switzerland.
Claudio SartiniBayer AG, Global Epidemiology, Berlin, Germany.
Kiliana Suzart-WoischnikBayer AG, Global Epidemiology, Berlin, Germany.
Rumjhum AgrawalNovartis Healthcare Pvt. Ltd., Hyderabad, India.
Harshul NataniNovartis Healthcare Pvt. Ltd., Hyderabad, India, harshul.natani@novartis.com.
Simrat K GillInstitute of Cardiovascular Sciences, University of Birmingham, Medical School, Vincent Drive, Birmingham, United Kingdom.
Sara Bruce WirtaNovartis Pharma AG, Novartis Campus, Basel, Switzerland.
Folkert W AsselbergsInstitute of Health Informatics, Institute of Cardiovascular Science & Health Data Research UK, University College London, London, United Kingdom.
Richard DobsonInstitute of Health Informatics, Institute of Cardiovascular Science & Health Data Research UK, University College London, London, United Kingdom.
Spiros DenaxasInstitute of Health Informatics, Institute of Cardiovascular Science & Health Data Research UK, University College London, London, United Kingdom.
Dipak KotechaInstitute of Cardiovascular Sciences, University of Birmingham, Medical School, Vincent Drive, Birmingham, United Kingdom.

Funding

British Heart Foundation PG/17/55/33087Medical Research Council MC_PC_17214Medical Research Council MR/K006584/1
6 · The paper itself

Abstract

backgroundTransparent and robust real-world evidence sources are increasingly important for global health, including cardiovascular (CV) diseases. We aimed to identify global real-world data (RWD) sources for heart failure (HF), acute coronary syndrome (ACS), and atrial fibrillation (AF).

methodsWe conducted a systematic review of publications with RWD pertaining to HF, ACS, and AF (2010-2018), generating a list of unique data sources. Metadata were extracted based on the source type (e.g., electronic health records, genomics, and clinical data), study design, population size, clinical characteristics, follow-up duration, outcomes, and assessment of data availability for future studies and linkage.

resultsOverall, 11,889 publications were retrieved for HF, 10,729 for ACS, and 6,262 for AF. From these, 322 (HF), 287 (ACS), and 220 (AF) data sources were selected for detailed review. The majority of data sources had near complete data on demographic variables (HF: 94%, ACS: 99%, and AF: 100%) and considerable data on comorbidities (HF: 77%, ACS: 93%, and AF: 97%). The least reported data categories were drug codes (HF, ACS, and AF: 10%) and caregiver involvement (HF: 6%, ACS: 1%, and AF: 1%). Only a minority of data sources provided information on access to data for other researchers (11%) or whether data could be linked to other data sources to maximize clinical impact (20%). The list and metadata for the RWD sources are publicly available at www.escardio.org/bigdata.

conclusionsThis review has created a comprehensive resource of CV data sources, providing new avenues to improve future real-world research and to achieve better patient outcomes.

Indexed as

Acute Coronary SyndromeAtrial FibrillationHeart FailureComorbidityHumansInformation Storage and RetrievalCardiovascularData sourcesReal-world dataReal-world evidence

Identifiers

PMID34781301
PMCPMC8985014

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.